Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005227235
Thu, 11.08.2022
Biotest AG
PRESS RELEASE
Biotest achieves an improved adjusted EBIT by 9.8% of € 32.4 million in the first half of 2022
Biotest almost reaches previous year's turnover of € 253 million in a difficult environment
Opening of four plasma collection centres in the 1st half of the year
More plasma centres planned in 2022
Dreieich, 11 August 2022. In the f [ … ]
Thu, 11.08.2022
Biotest AG
PRESS RELEASE
Biotest achieves an improved adjusted EBIT by 9.8% of € 32.4 million in the first half of 2022
Biotest almost reaches previous year's turnover of € 253 million in a difficult environment
Opening of four plasma collection centres in the 1st half of the year
More plasma centres planned in 2022
Dreieich, 11 August 2022. In the f [ … ]
Thu, 28.07.2022
Biotest AG
PRESS RELEASE
Biotest increases EBITDA in firsthalf-year by 52% to 8.8 million EUR
Biotest almost achieves previous year's sales in difficult environment
Opening of 4 plasma collection centres in the first half of the year
More plasma centres planned in 2022
Dreieich, 28 July 2022. In the first half of the financial year 2022, the [ … ]
Thu, 28.07.2022
Biotest AG
PRESS RELEASE
Biotest increases EBITDA in firsthalf-year by 52% to 8.8 million EUR
Biotest almost achieves previous year's sales in difficult environment
Opening of 4 plasma collection centres in the first half of the year
More plasma centres planned in 2022
Dreieich, 28 July 2022. In the first half of the financial year 2022, the [ … ]
Mon, 25.07.2022
Biotest AG
PRESS RELEASE
Biotest grants Renate & Hans Schleussner Research Award for the first time
Renate & Hans Schleussner Award endowed with € 50,000
Research project awarded for laboratory studies on the mode of action of cytomegalovirus (CMV) hyperimmunoglobulins in pregnancy to protect the unborn child
Biotest is currently als [ … ]
Mon, 25.07.2022
Biotest AG
PRESS RELEASE
Biotest grants Renate & Hans Schleussner Research Award for the first time
Renate & Hans Schleussner Award endowed with € 50,000
Research project awarded for laboratory studies on the mode of action of cytomegalovirus (CMV) hyperimmunoglobulins in pregnancy to protect the unborn child
Biotest is currently als [ … ]
Fri, 10.06.2022
Biotest AG
PRESS RELEASE
Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
Successful interim analysis after 120 patients
Number of patients originally planned for study confirmed
Results are the basis for approval in patients with severe blood loss after major surgery
Dreieich, 10 June 2022. Biotest AG announced t [ … ]
Thu, 09.06.2022
Biotest AG
PRESS RELEASE
Biotest AG opens 11th plasma collection centre in Czech Republic
31 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 9 June 2022. Biotest has received the operating license for its eleventh plasma collection centre in Czech Republic from the country's national public health authority SUKL.
The centre [ … ]
Tue, 24.05.2022
Biotest AG
PRESS RELEASE
Biotest AG opens 10th plasma collection centre in Czech Republic
30 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 24 May 2022. Biotest has received the operating license for its tenth plasma collection centre in Czech Republic from the country's national public health authority SUKL.
The centre is [ … ]
Fri, 06.05.2022
Biotest AG
PRESS RELEASE
Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG
Dreieich, 6 Mai 2022. At yesterday's Annual General Meeting of Biotest AG, the Supervisory Board was newly elected.
At the Annual General Meeting
- Ms. Uta Kemmerich-Keil,
- Mr. Xiaoying (David) Gao
- Dr Bernhard Ehmer
- Mr. Tan Yang
and as substitute members ap [ … ]